NDAINTRALYMPHATIC, INTRAUTERINEOILPriority Review
Approved
Mar 1954
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
4/8 — Partial
Priority Review
LIPIODOL (ethiodized oil) by Guerbet is x-ray contrast activity [moa]. Approved for radiographic contrast agent [epc]. First approved in 1954.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIPIODOL is an ethiodized oil radiographic contrast agent used for intralymphatic and intrauterine imaging in head and neck cancer diagnosis. It works through x-ray contrast activity to visualize lymphatic vessels and lymph nodes, enabling detection of metastatic involvement. This legacy small-molecule imaging agent has been the standard for lymphography since its approval in 1954.
LOE Approaching
As LOE approaches, brand team size is likely contracting; positions focus on defending legacy market share against advanced imaging modalities rather than growth.
Mechanism of Action
X-Ray Contrast Activity
Pharmacologic Class:
Radiographic Contrast Agent
Indications (1)
Clinical Trials (5)
Lipiodol Prior to FET (LIFE)
Started Aug 2024
784 enrolled
IVFFrozen Embryo TransferHysterosalpingography
Safety and Efficacy of a Lipiodol Emulsion for the Embolization of Hypervascularizations in Patients With Knee Pain (LipioJoint1)
Started Mar 2021
22 enrolled
Knee Osteoarthritis
Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial Injection of Idarubicin/Lipiodol Emulsion
Started Jul 2018
44 enrolled
Carcinoma, Hepatocellular
A Study to Evaluate How Safe and Effective is the Mixture of Lipiodol® Ultra Fluid and Glue When Used for Embolization Procedures
Started Nov 2017
132 enrolled
Congenital HemangiomaHemangioendotheliomaAngiosarcoma+1 more
Lipiodol as an Imaging Biomarker in Patients With Primary and Metastatic Liver Cancer
Started Apr 2013
39 enrolled
Liver Cancer
Worked on LIPIODOL at Guerbet? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.